Document Detail


Synthetic HDL as a new treatment for atherosclerosis regression: has the time come?
MedLine Citation:
PMID:  18378129     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Plasma high-density lipoprotein cholesterol (HDL-C) has received considerable attention as a potential therapeutic target to further reduce cardiovascular events in the statin era. One therapeutic approach to enhance HDL-mediated atheroprotection involves the use of small, synthetic and orally-active compounds that substantially raise plasma HDL-C levels. However, doubts on the clinical benefit achievable with such treatments have been raised by the premature termination of a large Phase III trial with torcetrapib, the most potent and furthest developed HDL-C raising compound, because of excess mortality in patients receiving the drug. The alternative is the direct administration of synthetic HDL (sHDL), discoidal lipoprotein particles which mimic most, if not all, of the atheroprotective properties of plasma HDL. Short-term treatments with sHDL of different composition caused consistent and remarkable reductions of atheroma volume in patients with acute coronary syndromes (ACS). Although at early stages of drug development, sHDL hold vast promise for plaque stabilization/regression, and cardiovascular event reduction.
Authors:
Paola Conca; Guido Franceschini
Related Documents :
10998479 - Influence of serum amyloid a on the decrease of high density lipoprotein-cholesterol in...
229879 - Hdl lipids in close relatives of coronary heart disease patients. environmental and gen...
20104929 - Should we take high-density lipoprotein cholesterol levels at face value?
222509 - Improved method for simultaneous determination of cholesterol in high- and low-density ...
15857309 - Cholesteryl ester transfer protein: pharmacological inhibition for the modulation of pl...
9677019 - Lipoprotein composition influences cholesteryl ester transfer in alcohol abusers.
15667849 - Effects of chlorpyrifos on reproductive performances of guppy (poecilia reticulata).
7319729 - Milk, cellular equilibrium and nutritional evolution.
7458679 - Intraindividual variability of plasma cholesterol and triglycerides and the effect of p...
Publication Detail:
Type:  Journal Article; Review     Date:  2008-04-18
Journal Detail:
Title:  Nutrition, metabolism, and cardiovascular diseases : NMCD     Volume:  18     ISSN:  1590-3729     ISO Abbreviation:  Nutr Metab Cardiovasc Dis     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-05-27     Completed Date:  2008-07-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111474     Medline TA:  Nutr Metab Cardiovasc Dis     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  329-35     Citation Subset:  IM    
Affiliation:
Center E. Grossi Paoletti, Department of Pharmacological Sciences, University of Milano, Via Balzaretti 9, 20133 Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / adverse effects*,  therapeutic use
Atherosclerosis / drug therapy*
Cholesterol, HDL / blood*,  drug effects,  therapeutic use*
Cholesterol, LDL / blood
Disease Progression
Humans
Quinolines / adverse effects*,  therapeutic use
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Quinolines; 262352-17-0/torcetrapib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pre-operative ordering of minimally invasive surgical tools: a fuzzy inference system approach.
Next Document:  The antidepressant role of dietary long-chain polyunsaturated n-3 fatty acids in two phases in the d...